Sigurdardottir, Vilborg

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2004 | 2002 | 1994

2015

Lesche, Dorothea; Sigurdardottir, Vilborg; Setoud, Raschid; Englberger, Lars; Fiedler, Georg M.; Largiadèr, Carlo R.; Mohacsi, Paul; Sistonen, Johanna (2015). Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation. Clinical transplantation, 29(12), pp. 1213-1220. Wiley-Blackwell 10.1111/ctr.12653

Arora, S; Andreassen, A K; Andersson, B; Gustafsson, F; Eiskjaer, H; Bøtker, H E; Rådegran, G; Gude, E; Ioanes, D; Solbu, D; Sigurdardottir, Vilborg; Dellgren, G; Erikstad, I; Solberg, O G; Ueland, T; Aukrust, P; Gullestad, L (2015). The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial. American journal of transplantation, 15(7), pp. 1967-1975. Wiley-Blackwell 10.1111/ajt.13214

Johansson, Inger; Andersson, Rune; Friman, Vanda; Selimovic, Nedim; Hanzen, Lars; Nasic, Salmir; Nyström, Ulla; Sigurdardottir, Vilborg (2015). Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients. BMC infectious diseases, 15(1), p. 582. BioMed Central 10.1186/s12879-015-1321-1

2014

Lesche, Dorothea; Sigurdardottir, Vilborg; Setoud, Raschid; Oberhänsli, Markus; Carrel, Thierry; Fiedler, Georg M; Largiadèr, Carlo Rodolfo; Mohacsi, Paul; Sistonen, Johanna (2014). CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients. Therapeutic drug monitoring, 36(6), pp. 710-715. Lippincott Williams & Wilkins 10.1097/FTD.0000000000000080

Andreassen, A K; Andersson, B; Gustafsson, F; Eiskjaer, H; Radegran, G; Gude, E; Jansson, K; Solbu, D; Sigurdardottir, Vilborg; Arora, S; Dellgren, G; Gullestad, L (2014). Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. American journal of transplantation, 14(8), pp. 1828-1838. Wiley-Blackwell 10.1111/ajt.12809

Gustafsson, Finn; Gude, Einar; Sigurdardottir, Vilborg; Aukrust, Pål; Solbu, Dag; Goetze, Jens-Peter; Gullestad, Lars (2014). Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels. Biomarkers in medicine, 8(2), pp. 239-245. Future Medicine 10.2217/bmm.13.95

2013

Zuckermann, Andreas; Wang, Shoei-Shen; Epailly, Eric; Barten, Markus J; Sigurdardottir, Vilborg; Segovia, Javier; Varnous, Shaida; Turazza, Fabio M.; Potena, Luciano; Lejmkuhl, Hans B. (2013). Everolimus immunosuppression in de novo heart transplant recipients: What does the evidence tell us now? Transplantation Reviews, 27(3), pp. 76-84. W.B. Saunders 10.1016/j.trre.2013.03.002

2012

Kornhall, Björn; Nilsson, Johan; Sigurdardottir, Vilborg; Dellgren, Göran; Hagerman, Inger; Hübbert, Laila (2012). [More heart transplantations than ever]. Läkartidningen, 109(39-40), pp. 1743-1744. Laekartidningen Foerlag

2011

Arora, Satish; Ueland, Thor; Wennerblom, Bertil; Sigurdardottir, Vilborg; Eiskjær, Hans; Bøtker, Hans E; Ekmehag, Bjorn; Jansson, Kjell; Mortensen, Svend-Aage; Saunamaki, Kari; Simonsen, Svein; Gude, Einar; Bendz, Bjørn; Solbu, Dag; Aukrust, Pål; Gullestad, Lars (2011). Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial. Transplantation, 92(2), pp. 235-243. Lippincott Williams & Wilkins 10.1097/TP.0b013e31822057f1

2009

Dellgren, Göran; Sigurdardottir, Vilborg; Berg, Claes-Håkan; Rundqvist, Bengt; Haraldsson, Asa; Berggren, Håkan; Lidén, Hans; Kjellman, Ulf; Karason, Kristjan; Wiklund, Lars; Andersson, Bert; Nilsson, Folke; Berglin, Eva (2009). [Better and better results of heart transplantation. Analysis of 25 years of collected experiences]. Läkartidningen, 106(49), pp. 3332-3337. Laekartidningen Foerlag

2008

Olson, F J; Schmidt, C; Gummesson, A; Sigurdardottir, Vilborg; Hulthe, J; Wiklund, O; Fagerberg, B (2008). Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis. Journal of internal medicine, 263(6), pp. 626-635. Blackwell Scientific Publications 10.1111/j.1365-2796.2008.01927.x

Sigurdardottir, Vilborg; Fagerberg, B; Wikstrand, J; Schmidt, C; Hulthe, J (2008). Circulating oxidized LDL is associated with the occurrence of echolucent plaques in the carotid artery in 61-year-old men. Scandinavian journal of clinical and laboratory investigation, 68(4), pp. 292-297. Taylor & Francis 10.1080/00365510701762723

2007

Simonsson, M; Schmidt, C; Sigurdardottir, Vilborg; Helenius, M-L; Fagerberg, B (2007). Life style habits such as alcohol consumption and physical activity in relation to serum apoB / apoA-I ratio amongst 64-year-old women with varying degrees of glucose tolerance. Journal of internal medicine, 262(5), pp. 537-544. Blackwell Scientific Publications 10.1111/j.1365-2796.2007.01866.x

Sigurdardottir, Vilborg; Fagerberg, Björn; Wikstrand, John; Schmidt, Caroline; Hulthe, Johannes (2007). Circulating oxidized low-density lipoprotein is associated with echolucent plaques in the femoral artery independently of hsCRP in 61-year-old men. Atherosclerosis, 190(1), pp. 187-193. Elsevier 10.1016/j.atherosclerosis.2006.01.016

2004

Sigurdardottir, Vilborg; Fagerberg, Björn; Hulthe, Johannes (2004). Preclinical atherosclerosis and inflammation in 61-year-old men with newly diagnosed diabetes and established diabetes. Diabetes care, 27(4), pp. 880-884. American Diabetes Association

2002

Sigurdardottir, Vilborg; Fagerberg, B; Hulthe, J (2002). Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). Journal of internal medicine, 252(5), pp. 440-447. Blackwell Scientific Publications

1994

Sigurdardottir, Vilborg; Einarsson, B; Sigfusson, N; Harðarson, T (1994). [The treatment of arterial hypertension in elderly men in Iceland]. Læknablađiđ, 80(10), pp. 520-528. Laeknafelag Islands

Provide Feedback